Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
19.22
+0.22 (1.16%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Wesley Kaupinen |
Contact Details
Address: 125 Strafford Avenue, Suite 360 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 253 1461 |
| Website | palvellatx.com |
Stock Details
| Ticker Symbol | PVLA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001742961 |
| ISIN Number | US6979471090 |
| Employer ID | 81-2228053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer and Director |
| Matthew E. Korenberg | Chief Financial Officer and Treasurer |
| Kathleen Goin | Chief Operating Officer |
| Dr. Braham Shroot Ph.D. | Chief Technical Officer |
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer |
| Bohan Wei | Vice President of Corporate Development and New Product Planning |
| Emily Cook | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2022 | D | Notice of Exempt Offering of Securities |
| Jun 3, 2020 | D | Notice of Exempt Offering of Securities |
| Aug 12, 2019 | D/A | Filing |
| Apr 12, 2019 | D | Notice of Exempt Offering of Securities |
| Jun 14, 2018 | D | Notice of Exempt Offering of Securities |